Product Name :
m-PEG8-Br
Description:
m-PEG8-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
CAS:
1056881-04-9
Molecular Weight:
447.36
Formula:
C17H35BrO8
Chemical Name:
25-bromo-2,5,8,11,14,17,20,23-octaoxapentacosane
Smiles :
COCCOCCOCCOCCOCCOCCOCCOCCBr
InChiKey:
CJXJMRATZFVXNX-UHFFFAOYSA-N
InChi :
InChI=1S/C17H35BrO8/c1-19-4-5-21-8-9-23-12-13-25-16-17-26-15-14-24-11-10-22-7-6-20-3-2-18/h2-17H2,1H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
m-PEG8-Br is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.|Product information|CAS Number: 1056881-04-9|Molecular Weight: 447.36|Formula: C17H35BrO8|Chemical Name: 25-bromo-2,5,8,11,14,17,20,23-octaoxapentacosane|Smiles: COCCOCCOCCOCCOCCOCCOCCOCCBr|InChiKey: CJXJMRATZFVXNX-UHFFFAOYSA-N|InChi: InChI=1S/C17H35BrO8/c1-19-4-5-21-8-9-23-12-13-25-16-17-26-15-14-24-11-10-22-7-6-20-3-2-18/h2-17H2,1H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.CNTF Protein, Human Description |Shelf Life: ≥12 months if stored properly.Omadacycline In Vivo |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:32757813 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.|References:|An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562Products are for research use only. Not for human use.|
